Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-identical Siblings for Severe Aplastic Anemia in Patients over 40 Years of Age

Overview

Journal Biol Blood Marrow Transplant

Date 2010 Apr 21

PMID 20403449

Citations 19

Authors

Dario Sangiolo

Rainer Storb

H Joachim Deeg

Mary E D Flowers

Paul J Martin

Brenda M Sandmaier

Hans-Peter Kiem

Richard A Nash

Kris Doney

Wendy M Leisenring

George Earl Georges

Affiliations

Soon will be listed here.

Abstract

Patients with severe aplastic anemia (SAA) over 40 years of age are often not offered treatment with hematopoietic cell transplantation (HCT) because of concerns about treatment-related morbidity or mortality. To evaluate this risk, we analyzed outcomes after allogeneic HCT from HLA-identical sibling donors for all older patients with SAA at our center since 1988. The 23 consecutive patients ranged in age from 40 to 68 years. The conditioning regimen was cyclophosphamide (200 mg/kg) and horse antithymocyte globulin. Methotrexate and cyclosporine were given for postgrafting immunosuppression. The cumulative incidences of grades II, III, and IV acute graft-versus-host-disease were 30%, 4%, and 0%, respectively; that for chronic GVHD was 26%. With a median follow-up of 9.1 years, overall survival was 65%. Documented infections within 1 month before HCT were significantly associated with risk of early treatment-related mortality (P < .001). The median time to discontinuation of posttransplant immunosuppression was 6.2 (range: 5.9-92.0) months. Three patients developed superficial basal cell carcinoma between 5.5 and 15 years after HCT. Our data favor a practice of extending HLA-identical sibling HCT for treatment of SAA in patients older than 40 years of age who are without significant medical comorbidities.

Citing Articles

Successful desensitization to horse antithymocyte globulin for aplastic anemia: two case reports and literature review.

Yuyama S, Oura M, Isezaki T, Ikeda D, Kitahara K, Funakoshi R J Pharm Health Care Sci. 2025; 11(1):15.

PMID: 40011965 PMC: 11866556. DOI: 10.1186/s40780-025-00421-w.

Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.

Amanam I, Otoukesh S, Al Malki M, Salhotra A Hematology Am Soc Hematol Educ Program. 2023; 2023(1):164-170.

PMID: 38066845 PMC: 10727045. DOI: 10.1182/hematology.2023000427.

Allogeneic bone marrow transplantation for aplastic anemia.

Storb R Int J Hematol. 2022; 119(3):220-230.

PMID: 36576660 PMC: 10300230. DOI: 10.1007/s12185-022-03506-6.

History of hematopoietic cell transplantation: challenges and progress.

Granot N, Storb R Haematologica. 2020; 105(12):2716-2729.

PMID: 33054108 PMC: 7716373. DOI: 10.3324/haematol.2019.245688.

Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation....

Elgohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H Bone Marrow Transplant. 2020; 55(10):1906-1917.

PMID: 32346079 DOI: 10.1038/s41409-020-0897-2.

References

Fukuda T, Boeckh M, Guthrie K, Mattson D, Owens S, Wald A . Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004; 10(7):494-503. DOI: 10.1016/j.bbmt.2004.02.006. View

Young N . Acquired aplastic anemia. Ann Intern Med. 2002; 136(7):534-46. DOI: 10.7326/0003-4819-136-7-200204020-00011. View

Frickhofen N, Heimpel H, Kaltwasser J, Schrezenmeier H . Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2002; 101(4):1236-42. DOI: 10.1182/blood-2002-04-1134. View

Rosenfeld S, Follmann D, Nunez O, Young N . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5. DOI: 10.1001/jama.289.9.1130. View

Tichelli A, Socie G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H . Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999; 130(3):193-201. DOI: 10.7326/0003-4819-130-3-199902020-00004. View

Scott B, Park J, Deeg H, Marr K, Boeckh M, Chauncey T . Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2008; 14(7):799-806. PMC: 2587376. DOI: 10.1016/j.bbmt.2008.04.011. View

Storb R, Etzioni R, Anasetti C, Appelbaum F, Buckner C, Bensinger W . Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994; 84(3):941-9. View

Young N, Bacigalupo A, Marsh J . Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2009; 16(1 Suppl):S119-25. PMC: 3521519. DOI: 10.1016/j.bbmt.2009.09.013. View

Kahl C, Leisenring W, Deeg H, Chauncey T, Flowers M, Martin P . Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005; 130(5):747-51. DOI: 10.1111/j.1365-2141.2005.05667.x. View

10.

Frickhofen N, Kaltwasser J, Schrezenmeier H, Raghavachar A, Vogt H, Herrmann F . Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991; 324(19):1297-304. DOI: 10.1056/NEJM199105093241901. View

11.

Doney K, Leisenring W, Storb R, Appelbaum F . Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med. 1997; 126(2):107-15. DOI: 10.7326/0003-4819-126-2-199701150-00003. View

12.

Kao S, Xu W, Brandwein J, Lipton J, Messner H, Minden M . Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol. 2008; 143(5):738-43. DOI: 10.1111/j.1365-2141.2008.07389.x. View

13.

Deeg H, Leisenring W, Storb R, NIMS J, Flowers M, Witherspoon R . Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998; 91(10):3637-45. View

14.

Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J . Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000; 37(1):69-80. DOI: 10.1016/s0037-1963(00)90031-3. View

15.

Camitta B, Thomas E, Nathan D, Santos G, Gordon-Smith E, Gale R . Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976; 48(1):63-70. View

16.

Storb R, Blume K, ODonnell M, Chauncey T, Forman S, Deeg H . Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001; 7(1):39-44. DOI: 10.1053/bbmt.2001.v7.pm11215697. View

17.

Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint M . Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988; 70(2):177-82. DOI: 10.1111/j.1365-2141.1988.tb02460.x. View

18.

Passweg J, Socie G, Hinterberger W, Bacigalupo A, BIGGS J, Camitta B . Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood. 1997; 90(2):858-64. View

19.

Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A . Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8. DOI: 10.3324/haematol.10075. View

20.

Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socie G . Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009; 94(9):1312-5. PMC: 2738727. DOI: 10.3324/haematol.2009.006916. View